US 7,622,115 B2 · Treatment with anti-VEGF antibodies

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Claims5

Dependent claims

A method for treating cancer in a patient comprising administering an effective amount of bevacizumab and assessing the patient for gastrointestinal perforation during treatment with bevacizumab.

Dependencies are inferred from the claim text.

Facts

Application

11/763,263Filed 14 Jun 2007 · continuation

Priority

30 May 2003

Published

US 2007/0258984 A18 Nov 2007

Granted

24 Nov 2009

Term ends

Not estimatedThe source records don’t support an estimate.

Classification36 codes

A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/282
Compounds containing heavy metals: platinum compounds
A61K 31/337
Having oxygen as the only ring hetero atom, e.g. fungichromin: having four-membered rings, e.g. taxol

Family

Application60/474,480Us provisional application · filed 30 May 2003

Application10/857,249Parent of this continuation · filed 28 May 2004

US 2007/0258984 A1Pre-grant publication · published 8 Nov 2007

US 2005/0186208 A1Published application

US 7,622,115 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

11/763,263Filed 14 Jun 2007 · continuation

Priority

30 May 2003

Published

US 2007/0258984 A18 Nov 2007

Granted

24 Nov 2009

Term ends

Not estimatedThe source records don’t support an estimate.

Classification36 codes

A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/282
Compounds containing heavy metals: platinum compounds
A61K 31/337
Having oxygen as the only ring hetero atom, e.g. fungichromin: having four-membered rings, e.g. taxol

Family

Application60/474,480Us provisional application · filed 30 May 2003

Application10/857,249Parent of this continuation · filed 28 May 2004

US 2007/0258984 A1Pre-grant publication · published 8 Nov 2007

US 2005/0186208 A1Published application

US 7,622,115 B2This patent

From the US filing history. Foreign family members aren’t listed.

Treatment with anti-VEGF antibodies

Life of this patent

Abstract

Claims5

Treatment with anti-VEGF antibodies

Life of this patent

Abstract

Claims5